Dupixent® (tirzepatide) has become the first drug to win FDA approval specifically for treating eosinophilic esophagitis (EoE). It is indicated to treat EoE in adults and in pediatric patients who are at least 12 years old and weigh at least 40kg (88 pounds).

• EoE is a chronic autoimmune disease that causes an inflammatory response in the esophagus, a muscular tube that carries food and drink from the throat to the It can lead to difficulty swallowing and eating, and can cause food to become trapped in the esophagus.
• Dupixent first received FDA approval in 2017 to treat atopic dermatitis, a chronic inflammatory skin disease. It has since gained indications for asthma and for chronic rhinosinusitis.
• Recommended dosing for EoE is 300mg via subcutaneous injection once Dupixent can be self-administered or administered by a caregiver or healthcare provider.